Online inquiry

IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ1983MR)

This product GTTS-WQ1983MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets PVRL4 gene. The antibody can be applied in Bladder Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_030916.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 81607
UniProt ID Q96NY8
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PVRL4, AGS-22CE(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ1983MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ254MR IVTScrip™ mRNA-Anti-EPCAM, 17-1A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA 17-1A
GTTS-WQ4389MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-224818
GTTS-WQ2969MR IVTScrip™ mRNA-Anti-IL33, ANB020(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ANB020
GTTS-WQ5677MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011 (DOX)(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CDX-011 (DOX)
GTTS-WQ3208MR IVTScrip™ mRNA-Anti-CD70, ARGX-110(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ARGX-110
GTTS-WQ1679MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ACZ885
GTTS-WQ2246MR IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ALX-0171
GTTS-WQ8124MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HH1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW